Consolidated Statements of Convertible Preferred Stock and Stockholders’ (Deficit) Equity - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit	Noncontrolling interests
Beginning balance (in shares) at Dec. 31, 2022	8,700,885
Beginning balance at Dec. 31, 2022	$ 107,808
Convertible preferred stock
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)	(8,700,885)
Conversion of convertible preferred stock and non-controlling interests to common stock	$ (107,808)
Ending balance (in shares) at Dec. 31, 2023	0
Ending balance at Dec. 31, 2023	$ 0
Beginning balance (in shares) at Dec. 31, 2022		2,217,737
Beginning balance at Dec. 31, 2022	(142,670)	$ 2	$ 1,197	$ (41)	$ (158,223)	$ 14,395
Stockholders’ (Deficit) Equity
Exercise of stock options (in shares)		128,716
Exercise of stock options	187		187
Stock-based compensation	2,316		2,316
Unrealized gain on marketable securities	440			440
Reclassification to net loss of previous unrealized gain on marketable securities	(399)			(399)
Issuance of common stock for cash in pre-closing financing (in shares)		3,730,608
Issuance of common stock for cash in pre-closing financing	30,640	$ 4	30,636
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability (in shares)		5,059,338
Issuance of common stock upon settlement of convertible promissory note, accrued interest, and related derivative liability	42,447	$ 5	42,442
Issuance of common stock to Sesen Bio shareholders in reverse capitalization (in shares)		10,374,272
Issuance of common stock to Sesen Bio shareholders in reverse capitalization	72,044	$ 10	72,034
Conversion of convertible preferred stock and non-controlling interests to common stock (in shares)		18,872,711
Conversion of convertible preferred stock and non-controlling interests to common stock	107,809	$ 19	122,185			(14,395)
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)		226,533
Sale of common stock under Open Market Sales Agreement, net of issuance costs	597		597
Net loss	(86,879)				(86,879)
Ending balance (in shares) at Dec. 31, 2023		40,609,915
Ending balance at Dec. 31, 2023	$ 26,532	$ 40	271,594	0	(245,102)	0
Ending balance (in shares) at Dec. 31, 2024	0
Ending balance at Dec. 31, 2024	$ 0
Stockholders’ (Deficit) Equity
Exercise of stock options (in shares)	3,810	3,810
Exercise of stock options	$ 4		4
Stock-based compensation	3,649		3,649
Unrealized gain on marketable securities	0
Reclassification to net loss of previous unrealized gain on marketable securities	0
Sale of common stock under Open Market Sales Agreement, net of issuance costs (in shares)		1,136,384
Sale of common stock under Open Market Sales Agreement, net of issuance costs	2,383	$ 1	2,382
Net loss	(60,477)				(60,477)
Ending balance (in shares) at Dec. 31, 2024		41,750,109
Ending balance at Dec. 31, 2024	$ (27,909)	$ 41	$ 277,629	$ 0	$ (305,579)	$ 0